Maria Luisa Balmer Wins the Marie Heim-Vögtlin Prize

Maria Luisa Balmer Wins the Marie Heim-Vögtlin Prize

Maria Luisa Balmer Wins the Marie Heim-Vögtlin Prize

The winner of this year’s Marie Heim-Vögtlin Prize is Maria Luisa Balmer. The SNSF is awarding her the prize for her research into intestinal bacteria and their role in the development of diabetes and morbid obesity.

In Switzerland, approximately one child in six is overweight, and the number is increasing. This is concerning, given that being severely overweight increases the risk of cardiovascular disease, cancer and diabetes. “We have known for some time that intestinal flora play a key role in the development of obesity,” says Maria Luisa Balmer, a specialist in Internal Medicine at Inselspital and head of a research group at the University of Bern. But the links are complex. In her research, Balmer is investigating the interactions between intestinal bacteria, their metabolic products and the immune system (*1).

In recognition of her research work, she has been awarded the Marie Heim-Vögtlin Prize 2023 by the Swiss National Science Foundation (SNSF). The award ceremony will take place at the University of Bern on 21 November.

Maria Luisa Balmer (Photo: Sina Lou Ravasio)

Identified: Fattening Bacteria

It is already known that morbidly obese people generally have different intestinal flora from slim, healthy people. Certain types of bacteria proliferate very vigorously, suppressing others as they do so. But what does that mean? And is the change in intestinal flora a cause or consequence of obesity? One of the researcher’s approaches to investigating these questions involves germ-free mice, which the University of Bern breeds in a facility that is unique in the world. “We can use these animals to investigate what effect individual bacterial species have and elucidate cause and effect relationships,” Balmer explains.

Using this approach, her team was actually able to identify five bacterial species that increase the susceptibility of the mice to obesity. As a next step, the team intends to investigate how this comes about – for example, which bacterial metabolic products contribute to the fattening effect, and what impact they have on the immune system.

In a preceding study, Balmer had already demonstrated that the metabolic product acetate has a positive effect on immune cells (*2). By doing so, she illustrated the link between diet, intestinal flora and the immune system, because one of the conditions under which acetate is formed is when bacteria in the intestines metabolise dietary fibre of the type contained in vegetables or wholegrain products.

Promoting health with chewing gum

Balmer’s research group is currently investigating the effect of dietary fibre in more detail in a clinical study involving over 100 severely obese children. The team has developed a chewing gum that has been enriched with water-soluble dietary fibre. And the best thing about this completely new idea is that the children do not realise the “FibreGum” is medicine. Like normal chewing gum, it tastes of mint. It is intended to promote intestinal metabolism in children almost without them noticing and at the same time help them reduce snacking on other sweets. “Low-threshold treatments are particularly important for children,” says Balmer. She hopes the study will demonstrate whether the nutritional fibre consumed with the FibreGum does actually improve intestinal flora, and ultimately whether it helps the children lose weight more easily.

Career snapshots: “We need a change of ideas”

Maria Luisa Balmer’s research already won her an SNSF Eccellenza Professorial Fellowship in 2020. She says she regards winning the Marie Heim-Vögtlin Prize as a huge accolade. But she also sees the prize as an opportunity to gain visibility as a researcher who is a doctor and mother as well. “As far as that’s concerned, our whole society needs an urgent rethink,” she emphasises. “We need to update our traditional role models for group leaders at higher education institutions because the bar for couples with jobs is unrealistically high for both mothers and fathers. I feel it is important to demonstrate that you can have a family or hobbies that demand a lot of time and still conduct cutting-edge research and be successful if you have people around you to support you.”

(*1) J. Lötscher and M.L. Balmer: Sensing between reactions – how the metabolic microenvironment shapes immunity. Clin Exp Immunol (2019). doi: https://doi.org/10.1111/cei.13291.

 

(*2) M.L. Balmer et. al: Memory CD8+ T Cells Balance Pro- and Anti-inflammatory Activity by Reprogramming Cellular Acetate Handling at Sites of Infection. Cell Matabolism (2020). doi: https://doi.org/10.1016/j.cmet.2020.07.004.

Contact

Maria Luisa Balmer

Universitätsklinik für Diabetologie, Endokrinologie, Ernährungsmedizin & Metabolismus (UDEM)

Inselspital

Freiburgstrasse 15

CH-3010 Bern

Tel.: +41 31 632 96 40

E-Mail: maria.balmer@unibe.ch

Award for outstanding women researchers

The SNSF awards the Marie Heim-Vögtlin (MHV) Prize each year to an outstanding young woman researcher. Prizewinners are inspiring role models who produced remarkable results and significantly progressed their careers while benefiting from an SNSF grant. Since 2020, the prize has been awarded to former female grantees of the MHV, Doc.CH, Postdoc.Mobility, Ambizione and PRIMA funding schemes.

Marie Heim-Vögtlin, who gave her name to the award, became the first Swiss woman to study medicine when she was admitted to the University of Zurich’s medical faculty in 1868. On completing her studies, she opened a gynaecological practice where she continued to work after giving birth to two children. She is regarded as one of the pioneers in the struggle to give women access to higher education.

https://www.snf.ch

Links

Contact

Maria Luisa Balmer

Universitätsklinik für Diabetologie, Endokrinologie, Ernährungsmedizin & Metabolismus (UDEM)

Inselspital

Freiburgstrasse 15

CH-3010 Bern

Tel.: +41 31 632 96 40

E-Mail: maria.balmer@unibe.ch

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

DCB Joins WHO Global Diabetes Compact Forum

DCB Joins WHO Global Diabetes Compact Forum

DCB Joins WHO Global Diabetes Compact Forum

DCB proudly joins the global efforts of the WHO Global Diabetes Compact Forum in line with its core vision and mission: To make life better for people living with diabetes.

DCB becomes new member of the WHO Global Diabetes Compact Forum

Recently, DCB was accepted as a new member of the WHO Global Diabetes Compact Forum. The principles and goals of the Forum align well with the DCB vision and mission – to make life better for people with diabetes.

DCB is delighted to join the global efforts, bringing a collective vision to advocacy and collaboration within the diabetes field. Within the Forum, ideas, information and views can be exchanged between WHO and members, as well as between members.

“The Global Diabetes Compact Forum was created by WHO to share ideas, information and views that help advocate for a world where the risk of diabetes is reduced and where all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable, quality treatment and care. ”

–  WHO

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

José García-Tirado on his diabetes research: Interview

José García-Tirado on his diabetes research: Interview

José García-Tirado on his diabetes research: Interview

DCB assistant professor José García-Tirado recently gave an interview on his diabetes research, providing insights into his career and the road that led him to Berne. You can now read the interview in German and French in the Swiss medium “d-journal”.

Interview with José García-Tirado on his diabetes research

Recently, the Swiss d-journal – a medium of the Swiss diabetes organisation diabetesschweiz – published an interview with DCB assistant professor José García-Tirado.

Since the beginning of 2023, José has been a professor specialising in diabetes technology at the University Department of Diabetology, Endocrinology, Nutritional Medicine and Metabolism (UDEM) and at the DCB (Diabetes Center Berne). Together with his team, he is involved in the development of even more precise therapies such as closed-loop systems for people with diabetes and other metabolic diseases.

In his interview, José speaks about his motivation for and background in diabetes research, and where he aims to take it in the next few years.

The interview is available as d-journal articles in German and French, and in our newsletter in English. Enjoy the read!

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

SNAQ and CarbVis join forces for better carb counting in diabetes

SNAQ and CarbVis join forces for better carb counting in diabetes

SNAQ and CarbVis join forces for better carb counting in diabetes

Bern, 3 October 2023 – SNAQ and CarbVis join forces for better diabetes management. CarbVis AG will be integrated into SNAQ AG, aiming to gain faster access to the market and to support the lives of people with diabetes more effectively. The new constellation enables the respective strengths to be used even better. The precise assessment of carbohydrates before each meal and their influence on blood glucose levels remain of central importance.

For people living with diabetes, estimating the amount of carbohydrates for appropriate insulin dosing is like a gamble sometimes. Decisions are often made based on experience and gut feeling, which can lead to mistakes1 with health consequences. For both CarbVis and SNAQ, the goal was to develop a technology that enables a quick and, above all, reliable calculation in a user-friendly way.

The two companies started with a different focus and have developed accordingly. SNAQ has an international focus and is now an established solution on the market. CarbVis emerged from a DCB-funded translational project in 2021, in collaboration with the University Department of Diabetology, Endocrinology, Nutritional Medicine and Metabolism (UDEM) of the Inselspital Bern and the University of Bern. After several years of technical and regulatory development, CarbVis has had a class 1 MDD medical device certified. In addition, the documents for the approval of a class 2 MDR medical device were submitted. The Qarbs app developed by CarbVis focused on safety and accuracy to achieve ease of integration with customers at B2B level. This complements SNAQ’s market presence and experience and extends the offering to B2C and B2B customers.

Added value for app users

“Uniting the two platforms is a logical development for us – we bring together our different strengths as well as business strategies and thus achieve a clear qualitative added value for the users of the app, medical professionals and our B2B partners,” emphasises the CEO of DCB and designated Chairman of the Board of Directors of SNAQ, Derek Brandt.

“The integration of CarbVis’ extensive regulatory and technical work will enable SNAQ to bring a dedicated insulin dosing solution to the European and US markets significantly faster,” said SNAQ CEO Aurelian Briner.

Image source: SNAQ

1 Buck S, Krauss C, Waldenmaier D, Liebing C, Jendrike N, Högel J, Pfeiffer BM, Haug C, Freckmann G. Evaluation of Meal Carbohydrate Counting Errors in Patients with Type 1 Diabetes. Exp Clin Endocrinol Diabetes. 2022 Jul;130(7):475-483. doi: 10.1055/a-1493-2324. Epub 2021 May 25. PMID: 34034353.

About DCB

Diabetes Center Berne (DCB) is a private, independent Swiss foundation established in 2017 with the aim of making life with diabetes easier. DCB supports ideas and projects in the field of diabetes technology worldwide by providing expertise, access to clinical research facilities and its own laboratories, as well as financial resources. The aim is to bring them a big step closer to market entry in a collaborative partnership. The work of the DCB is non-profit – the goal is new insights and innovations around diabetes management as well as a vibrant community.

About SNAQ

SNAQ’s diabetes platform enables patients and professionals to make data-based decisions around meals. The patented image analysis technology for estimating carbohydrates in meals has been validated in clinical trials and submitted for approval as a medical device in Europe. In the US, SNAQ is already an established solution with over 70,000 users.

Downloads

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

Greta Ehlers and Dr. Stefanie Hofer: Research & Patient Centricity

Greta Ehlers and Dr. Stefanie Hofer: Research & Patient Centricity

Greta Ehlers and Dr. Stefanie Hofer: Research & Patient Centricity

Recently, Greta Ehlers from our Business Development Team and Dr. Stefanie Hofer from our Clinical Research Team joined Tinotenda Dzikiti on his podcast “The Diabetic Mogul”, talking about research and patient centricity at DCB.

Research and Patient Centricity at DCB

In this podcast episode, Greta Ehlers and Dr. Stefanie Hofer from the DCB team give insights into their own lives with type 1 diabetes as well as their professional backgrounds in the diabetes field. In doing so, they specifically delve into the research we do at DCB and our strong commitment to patient centricity.

You can listen to the podcast below:

    Research & Patient Centricity are Essential

    About “The Diabetic Mogul” podcast

    “The Diabetic Mogul Podcast”, is hosted by Tinotenda Dzikiti (Certified Diabetes Educator) and Konstantina Taki (Medical Doctor) and who are Patient Advocates. Both Tino & Konna are co-hosting a series of podcast episodes, as they envision to inspire, empower, encourage and educate the community to prevent/manage diabetes. Their hope is that “everyone could get involved, get engaged, and come up together to create the change that this World needs.”

      More recent news

      Sign up for our newsletter and stay up to date.

      * Pflichtfelder
      DSGVO *

      DCB Research AG

      Freiburgstrasse 3
      3010 Bern
      Switzerland

      DCB on ADA TV: Driving Diabetes Technology Innovation

      DCB on ADA TV: Driving Diabetes Technology Innovation

      DCB on ADA TV: Driving Diabetes Technology Innovation

      As the American Diabetes Association’s 83rd Scientific Session are being held in San Diego, CA, from 23-26 June, a short movie about DCB’s mission of driving diabetes technology innovation will be broadcast across the convention center as well as conference hotels and shuttle busses.

      Learn more about DCB’s mission on ADA TV

      During the American Diabetes Association’s 83rd Scientific Session, a short movie about DCB’s mission will be broadcast across the convention center and associated areas. The movie produced for ADA TV features employees as well as associated research teams of DCB and brings the mission of driving diabetes technology innovation to screens all over.

      Other than on-site at the American Diabetes Association’s 83rd Scientific Sessions, it is also available to watch online:

      Driving Diabetes Technology Innovation - Diabetes Center Berne

      DCB thanks the American Diabetes Association and the production company WebsEdge Medicine for this great collaboration and for giving the DCB mission a stage at the ADA congress.

      More recent news

      Sign up for our newsletter and stay up to date.

      * Pflichtfelder
      DSGVO *

      DCB Research AG

      Freiburgstrasse 3
      3010 Bern
      Switzerland